AbCellera Biologics (ABCL) Current Taxes (2020 - 2022)

AbCellera Biologics has reported Current Taxes for 3 years, with the latest figure at $23.0 million in Q3 2022.

• For the quarter ending Q3 2022, Current Taxes rose 249.29% year-over-year to $23.0 million; the trailing twelve-month figure through Sep 2022 stood at $23.0 million (up 249.29% YoY), and the FY2021 full-year result was $35.7 million, down 1.3% from the prior year.
• Current Taxes for Q3 2022 stood at $23.0 million, down from $107.3 million in the prior quarter.
• The five-year high for Current Taxes was $107.3 million in Q2 2022, with the low at $5.8 million in Q2 2021.
• Historically, Current Taxes has averaged $43.8 million across 3 years, with a median of $32.9 million in 2021.
• Annual changes were most pronounced in 2021 — Current Taxes retreated 1.3% — and 2022, when it surged 1743.39%.
• AbCellera Biologics' Current Taxes stood at $36.2 million in 2020, then retreated by 1.3% to $35.7 million in 2021, then tumbled by 35.49% to $23.0 million in 2022.
• The last three Current Taxes figures came in at $23.0 million (Q3 2022), $107.3 million (Q2 2022), and $105.6 million (Q1 2022), per Business Quant data.